Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07075640 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. 3 versions Re-verified since May 28, 2026, no change to tracked fieldsv9-v11
  2. Trial status changed: Recruiting → Active, Not Recruiting Primary completion moved earlier from Mar 25, 2026 to Feb 11, 2026 · Site details revisedv8 Show 2 more changesShow less
    • Primary completion moved earlier from Mar 25, 2026 to Feb 11, 2026
    • Site details revised
  3. Re-verified, no change to tracked fieldsv7
  4. Primary completion date: Dec 8, 2025 to Mar 25, 2026 Completion date: Jan 13, 2026 to Aug 31, 2026v6 Show 1 more changeShow less
    • Completion date: Jan 13, 2026 to Aug 31, 2026
  5. Primary completion date: Nov 18, 2025 to Dec 8, 2025v5
Show 3 earlier versionsHide 3 earlier versions
  1. Primary completion date: Oct 17, 2025 to Nov 18, 2025 Completion date: Dec 12, 2025 to Jan 13, 2026v4 Show 1 more changeShow less
    • Completion date: Dec 12, 2025 to Jan 13, 2026
  2. 2 versions Re-verified since Aug 21, 2025, no change to tracked fieldsv2-v3
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary purpose of this study is to assess the safety and tolerability of a single dose of AG-236 administered subcutaneously in healthy participants.
Trial Details
NCT Number NCT07075640
Lead Sponsor Agios Pharmaceuticals, Inc.
Conditions Healthy Participants
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov